• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Gepotidacin 和 Zoliflodacin 如何稳定与细菌 IIA 拓扑异构酶结合的 DNA 断裂复合物?1. 金属结合位点的实验定义。

How Do Gepotidacin and Zoliflodacin Stabilize DNA Cleavage Complexes with Bacterial Type IIA Topoisomerases? 1. Experimental Definition of Metal Binding Sites.

机构信息

Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK.

Diamond Light Source, Harwell Campus, Didcot, Oxfordshire OX11 0DE, UK.

出版信息

Int J Mol Sci. 2024 Oct 30;25(21):11688. doi: 10.3390/ijms252111688.

DOI:10.3390/ijms252111688
PMID:39519241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11546367/
Abstract

One of the challenges for experimental structural biology in the 21st century is to see chemical reactions happen. () DNA gyrase is a type IIA topoisomerase that can create temporary double-stranded DNA breaks to regulate DNA topology. Drugs, such as gepotidacin, zoliflodacin and the quinolone moxifloxacin, can stabilize these normally transient DNA strand breaks and kill bacteria. Crystal structures of uncleaved DNA with a gepotidacin precursor (2.1 Å GSK2999423) or with doubly cleaved DNA and zoliflodacin (or with its progenitor QPT-1) have been solved in the same P6 space-group (a = b ≈ 93 Å, c ≈ 412 Å). This suggests that it may be possible to observe the two DNA cleavage steps (and two DNA-religation steps) in this P6 space-group. Here, a 2.58 Å anomalous manganese dataset in this crystal form is solved, and four previous crystal structures (1.98 Å, 2.1 Å, 2.5 Å and 2.65 Å) in this crystal form are re-refined to clarify crystal contacts. The structures clearly suggest a single moving metal mechanism-presented in an accompanying (second) paper. A previously published 2.98 Å structure of a yeast topoisomerase II, which has static disorder around a crystallographic twofold axis, was published as containing two metals at one active site. Re-refined coordinates of this 2.98 Å yeast structure are consistent with other type IIA topoisomerase structures in only having one metal ion at each of the two different active sites.

摘要

21 世纪实验结构生物学的挑战之一是观察化学反应的发生。()DNA 拓扑异构酶 IIA 可以在 DNA 拓扑结构的调控过程中产生暂时性的双链 DNA 断裂。药物,如 gepotidacin、zoliflodacin 和喹诺酮类药物 moxifloxacin,可以稳定这些通常短暂的 DNA 链断裂,并杀死细菌。未切割 DNA 与 gepotidacin 前体(2.1 Å GSK2999423)或双链切割 DNA 和 zoliflodacin(或其前体 QPT-1)的晶体结构已在相同的 P6 空间群(a = b ≈ 93 Å, c ≈ 412 Å)中得到解决。这表明,在这个 P6 空间群中,可能有可能观察到两个 DNA 切割步骤(和两个 DNA 连接步骤)。在这里,解决了该晶体形式的 2.58 Å 异常锰数据集,并重新精炼了该晶体形式的四个先前的晶体结构(1.98 Å、2.1 Å、2.5 Å 和 2.65 Å)以澄清晶体接触。这些结构清楚地表明存在单个移动金属机制——在一篇伴随的(第二篇)论文中提出。之前发表的一个酵母拓扑异构酶 II 的 2.98 Å 结构,在晶体学的二倍对称轴周围存在静态无序,被发表为在一个活性位点含有两个金属。这个 2.98 Å 酵母结构的重新精炼坐标与其他 IIA 拓扑异构酶结构一致,每个两个不同的活性位点仅含有一个金属离子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/0f5f8535472d/ijms-25-11688-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/e0edeecb93b5/ijms-25-11688-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/1fcbf9c7c393/ijms-25-11688-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/9d98a2baf8ae/ijms-25-11688-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/937acf13eae0/ijms-25-11688-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/5dc15a42543e/ijms-25-11688-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/0f5f8535472d/ijms-25-11688-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/e0edeecb93b5/ijms-25-11688-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/1fcbf9c7c393/ijms-25-11688-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/9d98a2baf8ae/ijms-25-11688-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/937acf13eae0/ijms-25-11688-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/5dc15a42543e/ijms-25-11688-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d1/11546367/0f5f8535472d/ijms-25-11688-g006.jpg

相似文献

1
How Do Gepotidacin and Zoliflodacin Stabilize DNA Cleavage Complexes with Bacterial Type IIA Topoisomerases? 1. Experimental Definition of Metal Binding Sites.Gepotidacin 和 Zoliflodacin 如何稳定与细菌 IIA 拓扑异构酶结合的 DNA 断裂复合物?1. 金属结合位点的实验定义。
Int J Mol Sci. 2024 Oct 30;25(21):11688. doi: 10.3390/ijms252111688.
2
A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with DNA Gyrase.佐利福定与 DNA 拓扑异构酶形成的 DNA 切割复合物的 2.8 Å 结构。
Int J Mol Sci. 2023 Jan 13;24(2):1634. doi: 10.3390/ijms24021634.
3
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.抗菌药物格帕沙星作用于金黄色葡萄球菌促旋酶的作用机制及结构基础
ACS Infect Dis. 2019 Apr 12;5(4):570-581. doi: 10.1021/acsinfecdis.8b00315. Epub 2019 Feb 28.
4
DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.DNA 拓扑异构酶抑制剂:捕获运动中的 DNA 切割机器。
J Mol Biol. 2019 Aug 23;431(18):3427-3449. doi: 10.1016/j.jmb.2019.07.008. Epub 2019 Jul 10.
5
Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide.金黄色葡萄球菌DNA促旋酶与QPT-1、莫西沙星和依托泊苷的共价DNA切割复合物的结晶及初步晶体学分析。
Acta Crystallogr F Struct Biol Commun. 2015 Oct;71(Pt 10):1242-6. doi: 10.1107/S2053230X15015290. Epub 2015 Sep 23.
6
Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.抗菌药物QPT-1、抗癌药物依托泊苷和莫西沙星对DNA回旋酶抑制作用的结构基础。
Nat Commun. 2015 Dec 7;6:10048. doi: 10.1038/ncomms10048.
7
Interactions between Zoliflodacin and Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting.唑利福定与拓扑异构酶 II 和拓扑异构酶 IV 的相互作用:细胞靶向的酶学基础。
ACS Infect Dis. 2024 Aug 9;10(8):3071-3082. doi: 10.1021/acsinfecdis.4c00438. Epub 2024 Jul 31.
8
Type IIA topoisomerase inhibition by a new class of antibacterial agents.新型抗菌药物对 IIA 拓扑异构酶的抑制作用。
Nature. 2010 Aug 19;466(7309):935-40. doi: 10.1038/nature09197. Epub 2010 Aug 4.
9
Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds.强效 DNA 拓扑异构酶抑制剂通过对称分叉的卤键不对称地结合其靶标。
Nat Commun. 2021 Jan 8;12(1):150. doi: 10.1038/s41467-020-20405-8.
10
Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.氟喹诺酮-拓扑异构酶-DNA 复合物:两种药物结合模式。
J Biol Chem. 2014 May 2;289(18):12300-12. doi: 10.1074/jbc.M113.529164. Epub 2014 Feb 4.

引用本文的文献

1
Structural and Mechanistic Insights into Atypical Bacterial Topoisomerase Inhibitors.非典型细菌拓扑异构酶抑制剂的结构与作用机制洞察
ACS Med Chem Lett. 2025 Apr 1;16(4):660-667. doi: 10.1021/acsmedchemlett.5c00060. eCollection 2025 Apr 10.
2
How Do Gepotidacin and Zoliflodacin Stabilize DNA-Cleavage Complexes with Bacterial Type IIA Topoisomerases? 2. A Single Moving Metal Mechanism.吉波达辛和佐利弗达辛如何与细菌IIA型拓扑异构酶稳定DNA切割复合物?2. 单一移动金属机制。
Int J Mol Sci. 2024 Dec 24;26(1):33. doi: 10.3390/ijms26010033.

本文引用的文献

1
Utilizing anomalous signals for element identification in macromolecular crystallography.利用异常信号进行大分子晶体学中的元素鉴定。
Acta Crystallogr D Struct Biol. 2024 Oct 1;80(Pt 10):713-721. doi: 10.1107/S2059798324008659. Epub 2024 Sep 18.
2
Interactions between Gepotidacin and Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting.Gepotidacin 与拓扑异构酶 IV 和拓扑异构酶 V 的相互作用:双重靶向平衡的遗传和生化证据。
ACS Infect Dis. 2024 Apr 12;10(4):1137-1151. doi: 10.1021/acsinfecdis.3c00346. Epub 2024 Mar 5.
3
Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions.
淋病奈瑟菌感染治疗失败的管理:当前指南和未来方向。
Lancet Infect Dis. 2024 Aug;24(8):e532-e538. doi: 10.1016/S1473-3099(24)00001-X. Epub 2024 Feb 14.
4
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.口服 gepotidacin 与硝基呋喃妥因治疗单纯性尿路感染患者(EAGLE-2 和 EAGLE-3):两项随机、对照、双盲、双模拟、3 期、非劣效性试验。
Lancet. 2024 Feb 24;403(10428):741-755. doi: 10.1016/S0140-6736(23)02196-7. Epub 2024 Feb 8.
5
Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against in a gonococcal hollow-fiber infection model.在淋球菌中空纤维感染模型中,左立氟达星联合多西环素治疗的药效学研究
Front Pharmacol. 2023 Dec 7;14:1291885. doi: 10.3389/fphar.2023.1291885. eCollection 2023.
6
Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens.一系列含茚满结构的新型NBTIs的发现及其对多重耐药革兰氏阴性病原菌的抗菌活性研究
ACS Med Chem Lett. 2023 Jun 22;14(7):993-998. doi: 10.1021/acsmedchemlett.3c00187. eCollection 2023 Jul 13.
7
The CCP4 suite: integrative software for macromolecular crystallography.Ccp4 套件:用于大分子晶体学的集成软件。
Acta Crystallogr D Struct Biol. 2023 Jun 1;79(Pt 6):449-461. doi: 10.1107/S2059798323003595. Epub 2023 May 30.
8
GEMMI and Servalcat restrain REFMAC5.GEMMI 和 Servalcat 限制了 REFMAC5 的使用。
Acta Crystallogr D Struct Biol. 2023 May 1;79(Pt 5):368-373. doi: 10.1107/S2059798323002413. Epub 2023 May 4.
9
A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with DNA Gyrase.佐利福定与 DNA 拓扑异构酶形成的 DNA 切割复合物的 2.8 Å 结构。
Int J Mol Sci. 2023 Jan 13;24(2):1634. doi: 10.3390/ijms24021634.
10
The Complex Interplay Between Antibiotic Resistance and Pharmaceutical and Personal Care Products in the Environment.抗生素耐药性与环境中的药品和个人护理产品之间的复杂相互作用。
Environ Toxicol Chem. 2024 Mar;43(3):637-652. doi: 10.1002/etc.5555. Epub 2023 Feb 8.